Vanda Pharmaceuticals (VNDA) Payables (2016 - 2025)
Vanda Pharmaceuticals (VNDA) has disclosed Payables for 16 consecutive years, with $68.3 million as the latest value for Q4 2025.
- Quarterly Payables rose 74.74% to $68.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $68.3 million through Dec 2025, up 74.74% year-over-year, with the annual reading at $68.3 million for FY2025, 74.74% up from the prior year.
- Payables hit $68.3 million in Q4 2025 for Vanda Pharmaceuticals, up from $47.6 million in the prior quarter.
- In the past five years, Payables ranged from a high of $68.3 million in Q4 2025 to a low of $26.1 million in Q1 2021.
- Historically, Payables has averaged $41.7 million across 5 years, with a median of $39.2 million in 2024.
- Biggest five-year swings in Payables: soared 96.87% in 2022 and later tumbled 36.44% in 2023.
- Year by year, Payables stood at $34.4 million in 2021, then skyrocketed by 32.27% to $45.6 million in 2022, then dropped by 15.57% to $38.5 million in 2023, then grew by 1.63% to $39.1 million in 2024, then soared by 74.74% to $68.3 million in 2025.
- Business Quant data shows Payables for VNDA at $68.3 million in Q4 2025, $47.6 million in Q3 2025, and $57.1 million in Q2 2025.